

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. North Kansas City Hospital 2. 2800 Clay Edwards Dr. North Kansas City, MO 64116		In accordance with letter dated March 09, 2021.	4. Expiration Date: February 28, 2022
		3. License No.: 24-18628-01 is amended in its entirety to read as follows:	5. Docket No.: 030-13966 Reference No.:
6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	B. For use in imaging and localization studies permitted by 10 CFR 35.200.
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1.5 curies total	C. For any use permitted by 10 CFR 35.300.
D. Any byproduct material permitted by 10 CFR 31.11	D. Prepackaged Kits	D. 5 millicuries total	D. For use in in-vitro studies.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-18628-01

Docket or Reference No.:
030-13966

Amendment No. 57

CONDITIONS

10. A. Licensed material in Subitem Nos. 6.A. through 6.D. shall be used at the licensee's facilities located at 2800 Clay Edwards Dr., North Kansas City, Missouri 64116.
- B. Licensed material listed in Subitem Nos. 6.A., 6.B. and 6.C. shall be used at the licensee's facilities located at 2790 Clay Edwards Dr., North Kansas City, Missouri 64116.
11. The Radiation Safety Officer for the activities authorized by this license is Karen Sweeney, R.T.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D., D.O., etc.)Material and Use

Srinivas R. Bapojé, M.D.

10 CFR 35.200

Andrew Boerkircher, D.O.

10 CFR 35.200

Marci Brecheisen, M.D.

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

David A. Feiock, M.D.

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200

Stephen Gimple, M.D.

10 CFR 35.200

Zafir A. Hawa, M.D.

10 CFR 35.200

Roger Ivey, M.D.

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Michael J. Krahn, M.D.

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

Rajya L. Malay, M.D.

10 CFR 35.200

James H. Mitchell, M.D.

10 CFR 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-18628-01

Docket or Reference No.:
030-13966

Amendment No. 57

Authorized User (M.D., D.O., etc.)

Julie J. Neperud, M.D.

Benjamin E. Northrup, M.D.

Patrick O'Keefe, M.D.

Zachary Shafer, M.D.

Jason D. Swink, M.D.

Ajay Tejwant, M.D.

Johnson Underwood, IV, M.D.

Timothy Waltner, M.D.

Material and Use

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

10 CFR 35.300 (limited to the parenteral administration of radium-223)

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to the oral administration of sodium iodide I-131)

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those statements, representations, and procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence impose on the licensee requirements that are more restrictive than or in addition to the regulations.

- A. Application dated August 18, 2011 (ML112312290)
- B. Letter dated December 14, 2011 (ML113620255)
- C. Letter dated January 3, 2012 (ML120340156)
- D. Letter dated January 6, 2012 (ML120340161)
- E. Letter dated January 9, 2012 (ML120590388)

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License No.: 24-18628-01

Amendment No. 57

Docket or Reference No.:
030-13966

- F. Letter dated January 11, 2012 (ML120120597)
G. Letter dated August 1, 2013 (ML13234A264)
H. Letter dated August 28, 2013 (ML13241A452)
I. Letter dated February 26, 2014 (ML14058A152)
J. Letter dated August 8, 2014 (ML14245A243)
K. Letter dated August 20, 2014 (ML14245A235)
L. Letter dated November 30, 2016 (ML16354A841)
M. Letter dated May 24, 2018 (ML18156A405)
N. Letter dated November 7, 2018 (ML18313A242)
O. Letter dated February 28, 2019 (ML19071A310)
P. Letter dated April 23, 2019 (ML19120A366)
Q. Letter dated June 19, 2019 (ML19175A034)
R. Letter dated June 25, 2019 (ML19177A074)
S. Letter dated August 9, 2019 (ML19221B625)
T. Letter dated August 9, 2019 (ML19227A341)
U. Letter dated March 9, 2021 (ML21093A237)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: May 21, 2021By: _____
Laura B. Cender
Region 3